<DOC>
	<DOCNO>NCT00934882</DOCNO>
	<brief_summary>This multi-center , open-label , non-randomized , non-placebo-controlled , Phase I study define safety profile tumor response profile multi-kinase inhibitor BAY73-4506 oral treatment combination chemotherapy regimen mFOLFOX6 FOLFIRI patient metastatic CRC . It also determine impact combine administration concentration drug time ( pharmacokinetics ) BAY73-4506 , oxaliplatin , 5 FU , irinotecan . This study conduct approximately 5 - 8 study center Germany . Up 60 patient enrol study ensute least 12 - 15 patient combination regimen evaluate safety pharmacokinetics . For reason minimum 20 patient receive mFOLFOX6 combination BAY73-4506 least 20 patient receive FOLFIRI combination BAY73-4506 .</brief_summary>
	<brief_title>Study Determine Safety , Pharmacokinetics , Pharmacodynamics BAY73-4506 Combination With mFOLFOX6 FOLFIRI</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histological cytological documentation adenocarcinoma colon rectum . At least 1 measurable lesion per RECIST ECOG Performance Status 0 1 Life expectancy least 12 week . Adequate bone marrow , liver , renal function More 1 previous chemotherapy Colorectal Cancer . Adjuvant chemotherapy Colorectal Cancer ( Stage I , II , II ) permit , adjuvant therapy end &gt; 6 month screening . Previous FOLFOX treatment patient include mFOLFOX6 cohort apart FOLFOX treatment adjuvant setting . Previous FOLFIRI treatment patient include FOLFIRI cohort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Multi-kinase inhibitor</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>